Wyoming
Prescription drug spending and prescribing in Wyoming, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $259M for prescriptions written in Wyoming, the 52nd most of 52 states and territories, and 4.6% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $259M
- Medicaid drugs, 2025: $43M
- Opioid share of claims: 4.6%
- Life-science raises, 2 years: $10M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Wyoming | United States | Difference |
|---|---|---|---|
| Opioids | 4.6% | 3.5% | +30% |
| Antibiotics | 4.5% | 4.4% | +2% |
| Antipsychotics | 1.6% | 1.7% | -6% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Wyoming's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Liothyronine Sodium | 2.4× | 2,239 |
| Desvenlafaxine Succinate | 2.0× | 2,412 |
| Morphine Sulfate | 1.8× | 6,069 |
| Warfarin Sodium | 1.8× | 11,487 |
| Potassium Chloride | 1.6× | 31,086 |
| Estradiol | 1.6× | 10,057 |
| Ropinirole Hcl | 1.5× | 6,727 |
| Levothyroxine Sodium | 1.5× | 93,651 |
| Prazosin Hcl | 1.5× | 2,438 |
| Cyclobenzaprine Hcl | 1.5× | 13,681 |
Biggest Medicaid Drugs
What Wyoming's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
4 Form D raises by companies based in Wyoming in the last two years; the 10 largest. See all raises- Nexia Impact Onshore 1 LP$6M · Biotech · Mar 27, 2026
- Lupvindol Biosciences LTD$2M · Biotech · Dec 23, 2024
- 352 Ingredients LLC$1M · Other health care · Nov 17, 2025
- MedNexus Health, Inc.$180K · Other health care · Aug 24, 2026
State Attorney General Health-Care Cases
Antitrust cases Wyoming joined, newest first; see every case- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
- Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL…2002 · Settled
- In the Matter of GlaxoSmithKline, PLC (Augmentin)Settled
- In Re Relafen Antitrust LitigationSettled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG